Trattamento con interferone beta 1b (IFN Beta 1b) e azatioprina nella sclerosi multipla relapsing remitting. Valutazione clinica e di qualita di vita

Roberto Palumbo; Andrea Salmaggi; Loredana L A Mantia; Alessandra Solari; Clara Milanese

Trattamento con interferone beta 1b (IFN Beta 1b) e azatioprina nella sclerosi multipla relapsing remitting. Valutazione clinica e di qualita di vita

Translated title of the contribution: Treatment with Interferon beta 1b and Azathioprine in the relapsing- remitting MS. Clinical and quality of life evaluation

Roberto Palumbo, Andrea Salmaggi, Loredana L A Mantia, Alessandra Solari, Clara Milanese

Fondazione IRCCS Istituto Neurologico "C. Besta"

Research output: Contribution to journal › Article › peer-review

Abstract

We prospectively evaluated relapse frequency and quality of life as assessed by the MS-QOL-54 questionnaire in 2 groups of relapsing-remitting MS patients with similar pre-treatment relapse rate and treated either with azathioprine or with beta IFN1b for one year. A marked reduction in relapse frequency occurred in both groups; no significant shifts occurred in the quality of life measurement. The results suggest further randomized studies of azathioprine and IFN beta in the therapy of relapsing-remitting MS.

Translated title of the contribution	Treatment with Interferon beta 1b and Azathioprine in the relapsing- remitting MS. Clinical and quality of life evaluation
Original language	Italian
Pages (from-to)	519-521
Number of pages	3
Journal	Rivista di Neurobiologia
Volume	45
Issue number	5-6
Publication status	Published - 1999

ASJC Scopus subject areas

Neuroscience(all)

Fingerprint Dive into the research topics of 'Treatment with Interferon beta 1b and Azathioprine in the relapsing- remitting MS. Clinical and quality of life evaluation'. Together they form a unique fingerprint.

Cite this

Trattamento con interferone beta 1b (IFN Beta 1b) e azatioprina nella sclerosi multipla relapsing remitting. Valutazione clinica e di qualita di vita. / Palumbo, Roberto; Salmaggi, Andrea; Mantia, Loredana L A; Solari, Alessandra; Milanese, Clara.

In: Rivista di Neurobiologia, Vol. 45, No. 5-6, 1999, p. 519-521.

Research output: Contribution to journal › Article › peer-review

@article{052e078497bf4beea3526c10b93528a8,

title = "Trattamento con interferone beta 1b (IFN Beta 1b) e azatioprina nella sclerosi multipla relapsing remitting. Valutazione clinica e di qualita di vita",

abstract = "We prospectively evaluated relapse frequency and quality of life as assessed by the MS-QOL-54 questionnaire in 2 groups of relapsing-remitting MS patients with similar pre-treatment relapse rate and treated either with azathioprine or with beta IFN1b for one year. A marked reduction in relapse frequency occurred in both groups; no significant shifts occurred in the quality of life measurement. The results suggest further randomized studies of azathioprine and IFN beta in the therapy of relapsing-remitting MS.",

keywords = "Azathioprine, IFN beta, MS, Quality of life, Relapse rate",

author = "Roberto Palumbo and Andrea Salmaggi and Mantia, {Loredana L A} and Alessandra Solari and Clara Milanese",

year = "1999",

language = "Italian",

volume = "45",

pages = "519--521",

journal = "Rivista Italiana di Neurobiologia",

issn = "0035-6336",

publisher = "Editrice Pisani s.a.s.",

number = "5-6",

}

TY - JOUR

T1 - Trattamento con interferone beta 1b (IFN Beta 1b) e azatioprina nella sclerosi multipla relapsing remitting. Valutazione clinica e di qualita di vita

AU - Palumbo, Roberto

AU - Salmaggi, Andrea

AU - Mantia, Loredana L A

AU - Solari, Alessandra

AU - Milanese, Clara

PY - 1999

Y1 - 1999

N2 - We prospectively evaluated relapse frequency and quality of life as assessed by the MS-QOL-54 questionnaire in 2 groups of relapsing-remitting MS patients with similar pre-treatment relapse rate and treated either with azathioprine or with beta IFN1b for one year. A marked reduction in relapse frequency occurred in both groups; no significant shifts occurred in the quality of life measurement. The results suggest further randomized studies of azathioprine and IFN beta in the therapy of relapsing-remitting MS.

AB - We prospectively evaluated relapse frequency and quality of life as assessed by the MS-QOL-54 questionnaire in 2 groups of relapsing-remitting MS patients with similar pre-treatment relapse rate and treated either with azathioprine or with beta IFN1b for one year. A marked reduction in relapse frequency occurred in both groups; no significant shifts occurred in the quality of life measurement. The results suggest further randomized studies of azathioprine and IFN beta in the therapy of relapsing-remitting MS.

KW - Azathioprine

KW - IFN beta

KW - MS

KW - Quality of life

KW - Relapse rate

UR - http://www.scopus.com/inward/record.url?scp=0033365107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033365107&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0033365107

VL - 45

SP - 519

EP - 521

JO - Rivista Italiana di Neurobiologia

JF - Rivista Italiana di Neurobiologia

SN - 0035-6336

IS - 5-6

ER -

Trattamento con interferone beta 1b (IFN Beta 1b) e azatioprina nella sclerosi multipla relapsing remitting. Valutazione clinica e di qualita di vita

Abstract

ASJC Scopus subject areas

Other files and links

Cite this